The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus

被引:122
作者
Janssen, M. F. [1 ]
Lubetkin, E. I. [2 ]
Sekhobo, J. P. [3 ]
Pickard, A. S. [4 ]
机构
[1] EuroQol Grp, EuroQol Execut Off, NL-3006 AK Rotterdam, Netherlands
[2] CUNY, Dept Community Hlth & Social Med, Sophie Davis Sch Biomed Educ, New York, NY 10021 USA
[3] New York State Dept Hlth, Evaluat & Anal Unit, Bur Adm & Evaluat, Div Nutr, Albany, NY USA
[4] Univ Chicago, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, Coll Pharm, Chicago, IL 60637 USA
关键词
diabetes; modelling; psychometrics; quality-of-life; QUALITY-OF-LIFE; GENERAL-POPULATION SURVEY; UTILITY VALUES; PERIPHERAL NEUROPATHY; SOCIODEMOGRAPHIC FACTORS; TREATMENT SATISFACTION; EUROQOL; PEOPLE; PAIN; RESPONSIVENESS;
D O I
10.1111/j.1464-5491.2010.03136.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Background The EQ-5D is a generic preference-based health status measure that has been widely applied to measure the impact of Type 2 diabetes mellitus. This review summarizes evidence on the validity, reliability and responsiveness of the EQ-5D in studies of Type 2 diabetes and provides a catalogue of EQ-5D index scores for Type 2 diabetes and various complications and subgroups. Methods A structured search was conducted (1987-2009) using keywords relevant to Type 2 diabetes and the EQ-5D. Original research studies in Type 2 diabetes that reported EQ-5D results and/or measurement properties were included. Results Of the 59 included articles, 54 publications reported EQ-5D responses and 39 papers presented evidence on the measurement properties of the EQ-5D. Studies that reported measurement properties supported construct, convergent and discriminant validity, test-retest reliability and responsiveness of the EQ-5D in Type 2 diabetes. Several studies reported a ceiling effect for the EQ-5D and an inability to capture multiple complications was observed. EQ-5D index scores ranged from 0.20 (severe diabetic peripheral neuropathic pain) to 0.88 (general population: good HbA(1c) level). For six subgroups, sufficient studies were available to calculate pooled mean index scores (95% CI): general population 0.67 (0.59-0.75), no complications 0.76 (0.68-0.83), microvascular complications 0.73 (0.57-0.89), macrovascular complications 0.73 (0.57-0.88), diabetic peripheral neuropathic pain 0.45 (0.39-0.51) and retinopathy 0.57 (0.46-0.69). Conclusions Evidence supported validity, reliability and responsiveness of the EQ-5D in Type 2 diabetes. EQ-5D index scores associated with Type 2 diabetes and various complications can be useful for modelling health outcomes in economic evaluations of health programmes for Type 2 diabetes.
引用
收藏
页码:395 / 413
页数:19
相关论文
共 92 条
[1]   Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes [J].
Armstrong, David G. ;
Chappell, Amy S. ;
Le, Trong K. ;
Kajdasz, Daniel K. ;
Backonja, Miroslav ;
D'Souza, Deborah N. ;
Russell, James M. .
PAIN MEDICINE, 2007, 8 (05) :410-418
[2]   Using the EuroQol 5-D in the Catalan General Population: Feasibility and Construct Validity [J].
X. Badia ;
A. Schiaffino ;
J. Alonso ;
M. Herdman .
Quality of Life Research, 1998, 7 (4) :311-322
[3]   Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data [J].
Bagust, A ;
Beale, S .
HEALTH ECONOMICS, 2005, 14 (03) :217-230
[4]   An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions [J].
Barton, Garry R. ;
Sach, Tracey H. ;
Doherty, Michael ;
Avery, Anthony J. ;
Jenkinson, Claire ;
Muir, Kenneth R. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (03) :237-249
[5]   The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naive Type 2 diabetes: A placebo-controlled, multicentre study [J].
Bech, P ;
Moses, R ;
Gomis, R .
QUALITY OF LIFE RESEARCH, 2003, 12 (04) :413-425
[6]   An off-the-shelf help list: A comprehensive catalog of preference scores from published cost-utility analyses [J].
Bell, CM ;
Chapman, RH ;
Stone, PW ;
Sandberg, EA ;
Neumann, PJ .
MEDICAL DECISION MAKING, 2001, 21 (04) :288-294
[7]   Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population [J].
Bharmal, Murtuza ;
Thomas, Joseph, III .
VALUE IN HEALTH, 2006, 9 (04) :262-271
[8]  
BOWMAN L, 2006, P 23 EUROQOL PLEN M, P437
[9]   Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes [J].
Boye, Kristina Secnik ;
Matza, Louis S. ;
Oglesby, Alan ;
Malley, Karen ;
Kim, Sunny ;
Hayes, Risa P. ;
Brodows, Robert .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[10]   Trends in the measurement of health utilities in published cost-utility analyses [J].
Brauer, Carmen A. ;
Rosen, Allison B. ;
Greenberg, Dan ;
Neumann, Peter J. .
VALUE IN HEALTH, 2006, 9 (04) :213-218